Kim J C, Lee K H, Yu C S, Kim H C, Kim J R, Chang H M, Kim J H, Kim J S, Kim T W
Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, 388-1 Poongnap-2-Dong Songpa-Ku, Seoul 138-736, South Korea.
Eur J Surg Oncol. 2004 Apr;30(3):271-9. doi: 10.1016/j.ejso.2003.12.002.
There are few studies reporting survival or recurrence patterns in colorectal cancer patients with inferior mesenteric lymph node metastasis (IMLN+). The present study evaluated the prognostic significance of patients being IMLN+ or IMLN- in colorectal cancer.
Survival, recurrence pattern and treatment protocols were compared between 63 IMLN+ patients and 108 IMLN- patients with stage III and IV rectal and sigmoid cancer undergoing curative surgery. Lymph node sampling was routinely performed prior to inferior mesenteric artery ligation and excision flush with aorta. Limited principal node dissection including IMLN was performed in cases of identified node metastasis.
The 5-year disease-free survival rates were 50% in IMLN- and 31% in IMLN+ patients (P=0.004). The 5-year disease-free survival rate was greater in the N1 group than the N2 group (P=0.038). Cox regression analysis showed IMLN+, lymphovascular tumour invasion, T4, M1, and pre-operative serum CEA level over 6 ng/ml were independently associated with unfavorable disease-free survival. The prognostic significance of M category was greater when the IMLN+ was included in the M1 as opposed to the N category. In patients undergoing absolute curative surgery, post-operative recurrence rates were 34% for IMLN- and 57% for IMLN+ patients (P=0.009; OR, 2.611; 95% CI, 1.313-5.194). For IMLN+ patients, post-operative adjuvant treatment independently correlated with disease-free survival (P=0.029).
IMLN+ is an independent survival factor enhancing the prognostic significance of the M category in the AJCC staging. Curative radical surgery and post-operative chemoradiotherapy appears to be warranted for IMLN+ colorectal cancer patients as it resulted in 5-year disease-free survival rates of up to 31% compared to 50% in IMLN- patients.
鲜有研究报道肠系膜下淋巴结转移(IMLN+)的结直肠癌患者的生存或复发模式。本研究评估了结直肠癌患者IMLN+或IMLN-的预后意义。
比较了63例IMLN+患者和108例IMLN-患者的生存、复发模式及治疗方案,这些患者均为接受根治性手术的Ⅲ期和Ⅳ期直肠及乙状结肠癌患者。在结扎肠系膜下动脉并与主动脉平齐切除之前常规进行淋巴结采样。对于确诊有淋巴结转移的病例,进行包括IMLN在内的有限主要淋巴结清扫。
IMLN-患者的5年无病生存率为50%,IMLN+患者为31%(P=0.004)。N1组的5年无病生存率高于N2组(P=0.038)。Cox回归分析显示,IMLN+、淋巴管肿瘤浸润、T4、M1以及术前血清癌胚抗原水平超过6 ng/ml与无病生存不良独立相关。当IMLN+被纳入M1而非N类别时,M类别的预后意义更大。在接受绝对根治性手术的患者中,IMLN-患者的术后复发率为34%,IMLN+患者为57%(P=0.009;OR,2.611;95%CI,1.313 - 5.194)。对于IMLN+患者,术后辅助治疗与无病生存独立相关(P=0.029)。
IMLN+是一个独立的生存因素,增强了AJCC分期中M类别的预后意义。对于IMLN+的结直肠癌患者,根治性手术和术后放化疗似乎是必要的,因为其5年无病生存率高达31%,而IMLN-患者为50%。